Abstract:TGF-β and related growth factors activate a broad range of cellular responses and play key roles in the pathogenesis of many diseases especially cancer, fibrotic diseases, autoimmune diseases, and parasitic diseases. The activity of the TGF-β-initiated signaling pathway is tightly controlled, for example, through regulation of the key downstream SMAD tumor suppressors. In response to TGF-β, SMADs are phosphorylated, which triggers a series of downstream signaling and gene transcriptional events in the nucleus. To maintain proper levels of activated SMADs, activated SMADs in the nucleus are normally dephosphorylated by nuclear phosphatase PPM1A and then transported back into the cytoplasm. However, it remains elusive how dephosphorylated SMADs are exported out of the nucleus to ensure the completion of the SMAD signaling termination. Objective: To discover and characterize the underlying pathway that completes the step of SMAD signaling termination. Methods: A combinatorial approach using biochemical, cell biological, and developmental methods was used in this study. Cells were manipulated with expression plasmids for various SMADs, PPM1A, and potential nuclear exporter RanBP3. Xenopus embryos were manipulated using standard protocols. The level of phosphorylated SMADs was performed by western blotting. Nuclear export of SMADs was examined by immunofluorescence microscopy, cell lysate fractionation and a novel reporter assay. Protein-protein interaction of SMADs and RanBP3 was assessed by biochemical assays (e.g. IP-Western) or fluorescence assays. Results: We determined the essential function of RanBP3 in selective nuclear export of SMAD2/3 in the TGF-β pathway. RanBP3 directly recognized dephosphorylated SMAD2/3, which results from the activity of nuclear SMAD phosphatase PPM1A; PPM1A enhanced the physical interaction between RanBP3 and SMAD2/3. We clearly demonstrated that RanBP3 mediated nuclear export of SMAD2/3 in a small G protein Ran-dependent manner. Consequently, increased expression of RanBP3 inhibited TGF-β signaling in mammalian cells and Xenopus embryos, and depletion of RanBP3 expression or dominant negative inhibition of RanBP3 enhanced TGF-β-induced anti-proliferative and transcriptional responses. Finally, we have found that RanBP3 itself was phosphorylated in response to mitogenic growth signals and this phosphorylation could fine-tune the function of RanBP3 in exporting SMADs. Conclusion: We have defined a key role for RanBP3 in selectively mediating SMAD nuclear export and terminating TGF-β signaling. Thus, our finding should provide insights into the mechanisms of TGF-β anti-cancer actions. Knowledge gained from these studies will be used to design novel therapeutic strategies for prevention and treatment of human cancer.

Coupling of dephosphorylation and nuclear export of Smads in TGF-beta signaling.

Post-translational regulation of TGF-β receptor and Smad signaling.

Post‐translational Regulation of TGF‐β Receptor and Smad Signaling

Posttranslational Regulation of Smads

Nuclear Export of Smad2 and Smad3 by RanBP3 Facilitates Termination of TGF-β Signaling

Coupled Actions of PPM1A and RanBP3 Terminate TGFβ/SMAD Tumor Suppressor Functions

Signaling Inputs Converge on Nuclear Effectors in TGF-β Signaling

Nuclear Export of Smads by RanBP3L Regulates Bone Morphogenetic Protein Signaling and Mesenchymal Stem Cell Differentiation.

Signaling Inputs Converge On Nuclear Effecters In Tgf-Beta Signaling

The nuclear import function of Smad2 is masked by SARA and unmasked by TGF beta-dependent phosphorylation

TGF-β Signalling from Cell Membrane to Nucleus Through SMAD Proteins

Receptor-activated transcription factors and beyond: multiple modes of Smad2/3-dependent transmission of TGF-β signaling

Termination of TGF-β Superfamily Signaling Through SMAD Dephosphorylation—A Functional Genomic View

TGF-β Induces Assembly of a Smad2–Smurf2 Ubiquitin Ligase Complex That Targets SnoN for Degradation

Systems theory of Smad signaling

Axin and GSK3- Control Smad3 Protein Stability and Modulate TGF- Signaling.

The mechanism of Smad2 and Smad3 in TGF-β1 signaling

Smad-dependent and Smad-independent pathways in TGF-β family signalling

Activation of Transforming Growth Factor-β Signaling by SUMO-1 Modification of Tumor Suppressor Smad4/DPC4*

TGF-β Signaling from Receptors to Smads

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.